drugset
drugset / Trial / NCT01427322

Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease

NCT01427322 ↗

Phase 0 Terminated 6 enrolled Virginia Commonwealth University
RandomizedParallel-groupOpen-labelTreatment

Summary

Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα), an important growth factor in cancer cell recovery after ionizing irradiation.

Timeline

Start
2011-09
Primary completion
2014-12
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule — Oral

Indications

epithelial neoplasm